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gists and rheumatologists, and treatment goals.  Conclusion: 
These recommendations can serve as a template for similar 
initiatives in other countries. At the same time, they high-
light the need to take into account the impact of the respec-
tive national health care system.  © 2015 S. Karger AG, Basel 
 Introduction 
 With a prevalence of around 2% in Caucasian popula-
tions, psoriasis (PsO) is among the most common dis-
eases in dermatological practice  [1] . In recent years, the 
fact that numerous other important diseases are associ-
ated with PsO, being more common among PsO patients 
than expected, is increasingly acknowledged  [2] . Psori-
atic arthritis (PsA) plays a particularly important role in 
this regard. PsA is a distinct type of spondyloarthritis, 
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 Abstract 
 Background: Psoriatic arthritis (PsA) substantially impacts 
the management of psoriatic disease.  Objective:  This study 
aimed to generate an interdisciplinary national consensus 
on recommendations of how PsA should be managed.  Meth-
ods: Based on a systematic literature search, an interdisci-
plinary expert group identified important domains and went 
through 3 rounds of a Delphi exercise, followed by a nominal 
group discussion to generate specific recommendations. 
 Results: A strong consensus was reached on numerous cen-
tral messages regarding the impact of PsA, screening proce-
dures, organization of the interaction between dermatolo-
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characterized by an involvement of the peripheral joints, 
axial skeleton, tendons or entheses in the presence of PsO 
 [3, 4] . PsA substantially increases the disease burden of 
PsO patients  [5] . In the majority of patients, PsA develops 
many years after the onset of PsO  [3] . Clinical decision 
making is substantially affected, as PsO patients usually 
need systemic therapies in the case of joint involvement, 
even if their skin symptoms are rather limited and poten-
tially manageable with topical therapies. In case of severe 
PsO, the presence of PsA might still affect the choice of 
systemic therapy.
 Despite the major clinical relevance of PsA, there are 
few guidelines or recommendations on its management. 
Several dermatology and rheumatology societies have is-
sued documents on its therapy  [6, 7] , some of them focus-
ing exclusively on the use of biologics  [8, 9] . The Group 
for Research and Assessment of Psoriasis and Psoriatic 
Arthritis was among the first to develop comprehensive 
treatment recommendations across all major clinical 
manifestations of PsO and PsA, addressing all therapeutic 
options available at the time  [10] . Furthermore, there are 
reviews that identify and summarize clinically important 
aspects beyond therapy, such as the need to routinely 
screen PsO patients for signs and symptoms of PsA  [11, 
12] . It is only now that recommendations on the joint 
management of PsO and PsA by dermatologists and 
rheumatologists are being developed in a well-structured 
manner, discussing not only therapy, but also diagnostics 
and collaborative long-term management  [13] . 
 Here, we report on the outcome of a Swiss national 
initiative, aiming at generating recommendations suffi-
ciently specific to be helpful in daily clinical practice and 
supporting high-quality long-term management of PsA 
patients.
 Materials and Methods 
 Literature Search  
 A PubMed search was performed in March 2013, using the 
terms ‘psoriasis’, ‘psoriatic arthritis’, ‘guideline’, ‘recommenda-
tion’ and ‘review’. The search covered articles published in English, 
German and French between January 1, 2000, and March 15, 2013. 
Additional potentially important reports were identified from the 
reference lists of seminal reviews.
 Experts 
 The expert group comprised 8 dermatologists and 8 rheuma-
tologists both from academic as well as non-academic institutions 
within Switzerland; all of these participants are regularly involved 
in the management of PsA patients. Out of this group, 2 derma-
tologists and 2 rheumatologists formed a working group, coordi-
nating the process of consensus building.
 Development of Recommendations  
 The above-mentioned working group performed the literature 
search and identified potential domains of interest. At a first face-
to-face meeting (May 2013), the number of relevant domains was 
reduced, and a list of 10 key questions was developed. Subsequent-
ly, each working group member generated suggestions for recom-
mendations on several relevant domains, based on the best avail-
able evidence identified as a result of the literature search. Number 
and wording of the recommendations were finalized at a second 
face-to-face meeting in June 2013. From July to September 2013, 3 
rounds of a Delphi exercise were completed. Recommendations 
were finalized during a formal group discussion in September 
2013, led by an independent professional moderator (D. Froide-
vaux, Froidevaux & Partner GmbH, Zurich, Switzerland). 
 Defining Consensus 
 The Delphi questionnaire offered 3 grades of disagreement 
(‘strongly disagree’, ‘disagree’, ‘slightly disagree’) plus 3 grades of 
agreement (‘slightly agree’, ‘agree’, ‘strongly agree’). Three rounds 
of questioning were performed, feeding back the results of each 
previous voting to the participants prior to the subsequent round. 
A vote was considered to reflect ‘consensus’ if >50% of the par-
ticipants voted ‘strongly disagree’/‘disagree’ or ‘agree’/‘strongly 
agree’. A vote was considered to reflect ‘strong consensus’ if >80% 
of the participants voted ‘strongly disagree’/‘disagree’ or ‘agree’/
‘strongly agree’. In the Results section below, the Delphi state-
ments reaching strong consensus are documented, and the evi-
dence on which this is based is summarized in  figure 1 .
 Results 
 Significance of PsA 
 Delphi statement: The prevalence of PsA has been un-
derestimated in the past (91% voted ‘agree’ or ‘strongly 
agree’) . This vote is based on epidemiological studies. 
While older publications indicated rather low prevalence 
rates  [3] , more recent investigations have revealed a much 
higher prevalence, along with a trend to underdiagnose 
PsA in dermatology clinics  [14–16] .
 Delphi statement: PsA contributes significantly to the 
morbidity of PsO patients (100% voted ‘agree’ or ‘strong-
ly agree’). The burden of PsA is now widely acknowl-
edged  [17] . PsA, compared with PsO alone, was associ-
ated with a significantly lower quality of life as assessed 
with the EuroQol 5-Dimension or the Health Assessment 
Questionnaire and with more fatigue as assessed with the 
Fatigue Severity Scale  [18, 19] . 
 Strategic Goal of Managing PsA 
 Delphi statement: The diagnosis of PsA needs to be 
established as early as possible (92% voted ‘agree’ or 
‘strongly agree’). The recommendation to undertake all 
efforts to diagnose PsA early is based on the observation 
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 Fig. 1. Synopsis of voting results on Delphi statements where a strong consensus was reached. 
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that about half of the PsA patients show a chronic pro-
gressive course  [20] . Moreover, there is emerging evi-
dence that early intervention yields better results  [21, 22] .
 Delphi statement: Dermatologists are in the position 
to early identify patients with PsA (100% voted ‘agree’ or 
‘strongly agree’). The important role of dermatologists as 
sentinels when it comes to the early detection of PsA is 
evident, given that PsA usually occurs many years after 
the onset of PsO  [3, 4] .
 Delphi statement: Presence or absence of PsA substan-
tially influences the choice of treatment (100% voted 
‘agree’ or ‘strongly agree’). The guidelines and recommen-
dations mentioned above underline the necessity for a sys-
temic therapy in almost all cases of PsA independent of 
the extent of PsO as well as the need to use, notably, tu-
mour necrosis factor α-inhibiting drugs fairly early to 
treat in particular clinical manifestations such as axial dis-
ease, enthesitis and dactylitis  [7, 10] . All this highlights the 
prominent role of PsA in choosing the optimal therapy.
 Establishing the Diagnosis of PsA 
 Delphi statement: Non-rheumatologists should ask 
PsO patients about joint and back pain (100% voted 
‘agree’ or ‘strongly agree’). Tender and/or swollen joints 
are clinical hallmarks of inflammatory joint diseases. 
Back pain, although a relatively non-specific symptom, 
often points towards axial involvement as a common fea-
ture of PsA  [23] .
 Delphi statement: Non-rheumatologists need to know 
the clinical manifestations of PsA (83% voted ‘agree’ or 
‘strongly agree’). PsA, like PsO, shows a wide range of 
clinical manifestations. These include the involvement of 
the peripheral joints, axial skeleton, enthesitis, dactylitis 
and uveitis. Awareness of these clinical signs helps to rec-
ognize PsA  [24] .
 Delphi statement: Non-rheumatologists should not 
perform imaging, such as X-ray, magnetic resonance im-
aging or ultrasound (92% voted ‘disagree’ or ‘strongly dis-
agree’ on the initial proposal that non-rheumatologists 
should do so). Although several dermatology groups re-
ported on ultrasound and PsA  [25] , this expertise is rath-
er limited among non-specialists.
 Management of PsA 
 Delphi statement: Rheumatologists should confirm 
the diagnosis of PsA suspected by non-rheumatologists 
(92% voted ‘agree’ or ‘strongly agree’). Like PsO, PsA is 
an incurable and often severe disease as a substantial per-
centage of patients show a chronic progressive course 
 [20] . The diagnosis therefore needs to be well established.
 Delphi statement: Introduction of disease-modifying 
antirheumatic drug (DMARD) treatment by dermatolo-
gists needs to be discussed with the rheumatologists (83% 
voted ‘agree’ or ‘strongly agree’). The efficacy of DMARDs 
on skin and joint symptoms is quite diverse: while meth-
otrexate is considered to be fairly effective on PsO  [26] , 
leflunomide – which is regarded as an effective therapy 
for PsA – has shown insufficient efficacy on skin symp-
toms to warrant its use in dermatology  [27] . Moreover, 
DMARDs have shown insufficient efficacy in certain 
common clinical manifestations of PsA, namely axial in-
volvement, dactylitis and enthesitis  [28] . The resulting 
treatment algorithm proposed by rheumatologists is 
complex  [7] and the treatment should therefore be tai-
lored according to the leading symptoms in each indi-
vidual case. 
 Delphi statement: Dermatologists and rheumatolo-
gists need to jointly follow PsA patients. This concept 
provided the basis for the initiative reported here and was 
therefore not voted upon. All participants opted for a 
flexible rather than a predefined cooperation between the 
specialized fields, giving priority to the clinical course and 
emerging issues on the patients’ side.
 Delphi statement: Proven efficacy in PsO and PsA is a 
substantial advantage for a drug to be used in treating pa-
tients with PsO and/or PsA (84% voted ‘agree’ or ‘strong-
ly agree’). Drugs that allow to treat many different clinical 
manifestations of PsO and/or PsA help to reduce the 
number of drugs a patient needs to take. This is of direct 
clinical relevance, as comorbidity and resulting comedi-
cation is a common problem in PsO patients and mini-
mizing the likelihood for drug-drug interactions is there-
fore regarded as important  [2, 26] . Moreover, simplifying 
the treatment regimen is likely to increase patient adher-
ence  [29] . 
 Delphi statement: The treatment goal should be min-
imal residual disease (100% voted ‘agree’ or ‘strongly 
agree’). Minimal residual disease is defined by the Out-
come Measures in Rheumatology group as ‘a state which 
is deemed a useful target of treatment by both physician 
and patient, given current treatment possibilities and lim-
itations’  [30] . Specific criteria have been developed to de-
fine minimal disease activity in PsA  [31] and have been 
subsequently validated  [32] . PsA patients treated with 
this goal in mind commonly show less structural joint 
damage than those receiving standard care  [33] . 
 Delphi statement: Treatment response has to be as-
sessed regularly (around every 3 months), and treatment 
must be adapted accordingly (100% voted ‘agree’ or 
‘strongly agree’). Disease assessment is routine in rheu-
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matology, while dermatology lacks this ‘culture of assess-
ment’. Only recently did a group of European experts 
suggest defining treatment goals for PsO and regularly 
assessing the extent to which these are met through treat-
ment, advocating timely adaptions if needed  [34] . The 
above Delphi statement underlines the need for such a 
structured approach, not only with regard to PsA, but also 
for PsO.
 Discussion 
 Here, we summarize Delphi statements on the impact 
of PsA and its (early) diagnosis and management. These 
Delphi statements were developed in a structured way 
and yielded a strong consensus, defined as  ≥ 80% agree-
ment of the working group ( fig. 1 ). Those issues where no 
consensus was reached were useful to identify areas re-
quiring further research, as there was either a lack of evi-
dence or newer findings that might not be generally ap-
plicable yet.
 For example, the group underlined the importance of 
PsA as a comorbidity of PsO not only because of its (high-
er than previously estimated) prevalence, but also be-
cause of its impact on the burden of disease. At the same 
time, the group did not agree on the impact of PsA on PsO 
patients’ mortality. Although a recent systematic review 
pointed towards an increased cardiovascular risk among 
PsA patients  [35] , we found it difficult to attribute this to 
PsA as such rather than to coexisting PsO, known to ex-
hibit increased cardiovascular mortality  [36] , or to the 
therapeutic measures taken. Another example is the con-
cept of a window of opportunity, which is well established 
for rheumatoid arthritis, where early effective therapy re-
sults in a superior long-term outcome  [37] . For PsA, there 
is preliminary evidence that therapies might be more ef-
fective in patients with a shorter disease duration  [22] ; but 
data on long-term outcomes are not yet available. The 
observation of Haroon et al.  [38] that even a 6-month de-
lay from symptom onset to the first visit with a rheuma-
tologist contributes to the development of peripheral 
joint erosions and worse long-term physical function 
points into the same direction.
 A clinically most important point is the question of 
how to diagnose PsA, especially when this is being done 
by dermatologists. There was no strong consensus within 
this group in favour of screening questionnaires, although 
several had been developed and validated exactly for that 
purpose, all of them claiming very good sensitivity in the 
order of 90%  [38] . However, subsequent comparative 
studies, using several well-established questionnaires in 
different settings, were inconsistent  [15, 39] . Therefore, 
the working group suggested to systematically ask pa-
tients about joint and back pain instead. 
 Similarly important is the question of whether or not 
there is a gold standard for treating PsA. For decades, 
methotrexate has been widely used as the DMARD of 
choice for treating PsA. Recently, a large randomized pla-
cebo-controlled trial found no evidence for the most fre-
quently applied weekly oral methotrexate improving sy-
novitis; the authors raised the question about its classifi-
cation as a DMARD  [40] . This publication sparked a 
lively discussion in the scientific literature, and our work-
ing group did not come to a conclusive vote on this issue 
either. The Delphi statement ‘methotrexate remains the 
gold standard for peripheral PsA’ was voted ‘agreed’ by 
33%, ‘slightly agreed’ by 33%, ‘slightly disagreed’ by 17%, 
‘disagreed’ by 8% and ‘strongly disagreed’ by another 8%. 
This underlines that rheumatologists and dermatologists 
need to continuously discuss in detail important studies 
on key aspects of managing PsO and PsA.
 One strength of the initiative presented here is the pro-
cess by means of which the consensus statements were 
obtained. An interdisciplinary approach was ensured 
from the very beginning through the establishment of a 
working group of 2 rheumatologists and 2 dermatologists 
assigned to identify and discuss relevant domains, based 
on a comprehensive literature search. Three subsequent 
Delphi rounds plus a nominal group discussion led by an 
independent professional moderator made sure every ex-
pert was heard and provided his input on the final result. 
The statements reaching strong consensus are thus trust-
worthy.
 One limitation of this initiative is that the Delphi state-
ments reflect the beliefs of a group of experts that took 
into account the Swiss health care system. This system is 
characterized by an equal number of rheumatologists and 
dermatologists, each specialized field being represented 
by a sufficiently high number of physicians to ensure 
timely consultation for every Swiss citizen. This is in con-
trast to most other countries, where dermatologists out-
number rheumatologists by far  [5] . The resulting impli-
cations include different priorities, especially with regard 
to the screening and transferal of PsA patients: while in 
most countries the screening physician’s (often the der-
matologist’s) task includes attempts to ‘protect’ rheuma-
tologists from patients with non-inflammatory joint dis-
ease (e.g. osteoarthritis or fibromyalgia), Swiss rheuma-
tologists are in the position to confirm (or correct) the 
transferring non-rheumatologist’s diagnosis, also in the 
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case of non-inflammatory joint disease (hence the con-
sensus on asking relatively poorly discriminating ques-
tions on joint and back pain). This implies that in most 
health care systems, specificity remains an important cri-
terion for PsA screening tools such as questionnaires, 
while this seems less of an issue in systems like the Swiss 
health care system. However, considerations regarding 
the respective health care system where any given guide-
line or recommendation should be implemented are cru-
cial to guarantee feasibility. Looking at the trend to pub-
lish more and more international recommendations and 
even guidelines, we are worried that in an attempt to be 
‘universally applicable’, the respective recommendations 
become too general and thus less and less helpful.
 Taken together, the Delphi statements summarized 
here were primarily developed with the intention to help 
Swiss rheumatologists and dermatologists to jointly sup-
port their PsA patients in the best possible way. However, 
practicing physicians outside Switzerland might find sev-
eral of the Delphi statements helpful for their own work. 
Last but not least, colleagues may feel encouraged to re-
flect on the benefits and limitations of international rec-
ommendations and guidelines.
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